The FDA has approved dextromethorphan-bupropion extended-release tablets for agitation associated with Alzheimer disease dementia, offering clinicians a non-antipsychotic treatment option supported by...
A meta-analysis published in GeroScience evaluated data from 23 studies to determine the impact of adherence to the Mediterranean diet on the risk of cognitive impairment, dementia, and Alzheimer disease....
In a recent study, exposure to fine particulate matter (PM2.5) was associated with both more advanced Alzheimer disease neuropathologic change and greater dementia severity, with much of this link mediated...
In a phase 3 randomized controlled trial, escitalopram was not associated with significant improvement in agitation symptoms in patients with Alzheimer dementia and was linked to QT interval prolongation,...
A large cohort study explored whether semaglutide and tirzepatide influence risks of dementia, stroke, and survival in adults with diabetes and obesity.
Agitation in frontotemporal lobar degeneration is linked to distinct neuropsychiatric symptom profiles between men and women, with men showing a broader spectrum of associated symptoms, particularly in...
New clinical guidance outlines the use of blood-based biomarker tests for Alzheimer’s diagnosis in patients with cognitive impairment, aiming to support more consistent and evidence-based application in...
In a recent multicenter study, brexpiprazole showed significant efficacy in reducing agitation symptoms in Japanese patients with Alzheimer dementia, marking the first confirmation of its effectiveness in...
Researchers analyzed patient data from the Alzheimer’s Disease in Down Syndrome study to determine the sex differences in Alzheimer-related neuropsychiatric symptomology among adults with Down syndrome.
...
Researchers set out to determine whether attention-deficit/hyperactivity disorder predisposes individuals to the development of neuropsychiatric symptoms. The researchers presented their findings at the...
